{"id":5543,"date":"2021-03-15T15:27:09","date_gmt":"2021-03-15T14:27:09","guid":{"rendered":"https:\/\/www.idsein.fr\/breast-cancer-breast-reconstruction\/treatments\/traitements-medicaux\/therapeutiques-ciblees\/"},"modified":"2026-01-05T13:46:45","modified_gmt":"2026-01-05T12:46:45","slug":"targeted-therapies","status":"publish","type":"page","link":"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/","title":{"rendered":"Targeted therapy"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Anti-HER2 treatments can only be given to women with HER2-overexpressed breast cancer: 10-15% of breast cancers express a large number of HER2 receptors on their surface. They are called HER2 positive or HER2 overexpressed or HER2 amplified. This is determined by pathological examination of the <\/span><b>biopsy <\/b><span style=\"font-weight: 400;\">or surgical specimen.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Pertuzumab (Perjeta\u00ae) is, like trastuzumab, an antibody specifically directed against HER2 receptors. It has a similar mechanism of action.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">It is primarily used in metastatic breast cancer, HER2 overexpressed, as an adjunct to trastuzumab, and in advanced breast cancer.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Cyclin-dependent kinase inhibitors have become very important in the treatment of hormone-dependent and HER2-negative breast cancer at a metastatic or advanced stage. They act on enzymes, cyclin-dependent kinases 4\/6, which play a role in the cell division cycle.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anti-HER2 treatments can only be given to women with HER2-overexpressed breast cancer: 10-15% of breast cancers express a large number of HER2 receptors on their surface. They are called HER2 positive or HER2 overexpressed or HER2 amplified. This is determined by pathological examination of the biopsy or surgical specimen. Pertuzumab (Perjeta\u00ae) is, like trastuzumab, an [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":5494,"menu_order":0,"comment_status":"open","ping_status":"closed","template":"page-templates\/internal-page.php","meta":{"footnotes":""},"class_list":["post-5543","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Targeted therapies in treatment of breast cancer | Breast Institute Paris - Restitute<\/title>\n<meta name=\"description\" content=\"The Breast Institute Paris - Restitute offers targeted therapies to stop tumor development and limit the adverse effects of breast cancer treatment. Learn about these treatments: trastuzumab, lapatinib, palbociclib and many more\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Targeted therapies in treatment of breast cancer | Breast Institute Paris - Restitute\" \/>\n<meta property=\"og:description\" content=\"The Breast Institute Paris - Restitute offers targeted therapies to stop tumor development and limit the adverse effects of breast cancer treatment. Learn about these treatments: trastuzumab, lapatinib, palbociclib and many more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"L&#039;institut du Sein Paris Restitute\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-05T12:46:45+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/\",\"url\":\"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/\",\"name\":\"Targeted therapies in treatment of breast cancer | Breast Institute Paris - Restitute\",\"isPartOf\":{\"@id\":\"https:\/\/www.idsein.fr\/#website\"},\"datePublished\":\"2021-03-15T14:27:09+00:00\",\"dateModified\":\"2026-01-05T12:46:45+00:00\",\"description\":\"The Breast Institute Paris - Restitute offers targeted therapies to stop tumor development and limit the adverse effects of breast cancer treatment. Learn about these treatments: trastuzumab, lapatinib, palbociclib and many more\",\"breadcrumb\":{\"@id\":\"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.idsein.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cancer and reconstruction\",\"item\":\"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Breast cancer treatments\",\"item\":\"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Medical treatments\",\"item\":\"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Targeted therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.idsein.fr\/#website\",\"url\":\"https:\/\/www.idsein.fr\/\",\"name\":\"L&#039;institut du Sein Paris Restitute\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.idsein.fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Targeted therapies in treatment of breast cancer | Breast Institute Paris - Restitute","description":"The Breast Institute Paris - Restitute offers targeted therapies to stop tumor development and limit the adverse effects of breast cancer treatment. Learn about these treatments: trastuzumab, lapatinib, palbociclib and many more","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/","og_locale":"en_US","og_type":"article","og_title":"Targeted therapies in treatment of breast cancer | Breast Institute Paris - Restitute","og_description":"The Breast Institute Paris - Restitute offers targeted therapies to stop tumor development and limit the adverse effects of breast cancer treatment. Learn about these treatments: trastuzumab, lapatinib, palbociclib and many more","og_url":"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/","og_site_name":"L&#039;institut du Sein Paris Restitute","article_modified_time":"2026-01-05T12:46:45+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/","url":"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/","name":"Targeted therapies in treatment of breast cancer | Breast Institute Paris - Restitute","isPartOf":{"@id":"https:\/\/www.idsein.fr\/#website"},"datePublished":"2021-03-15T14:27:09+00:00","dateModified":"2026-01-05T12:46:45+00:00","description":"The Breast Institute Paris - Restitute offers targeted therapies to stop tumor development and limit the adverse effects of breast cancer treatment. Learn about these treatments: trastuzumab, lapatinib, palbociclib and many more","breadcrumb":{"@id":"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/targeted-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.idsein.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Cancer and reconstruction","item":"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/"},{"@type":"ListItem","position":3,"name":"Breast cancer treatments","item":"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/"},{"@type":"ListItem","position":4,"name":"Medical treatments","item":"https:\/\/www.idsein.fr\/en\/cancer-and-reconstruction\/treatments\/medical-treatments\/"},{"@type":"ListItem","position":5,"name":"Targeted therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.idsein.fr\/#website","url":"https:\/\/www.idsein.fr\/","name":"L&#039;institut du Sein Paris Restitute","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.idsein.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.idsein.fr\/en\/wp-json\/wp\/v2\/pages\/5543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.idsein.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.idsein.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.idsein.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.idsein.fr\/en\/wp-json\/wp\/v2\/comments?post=5543"}],"version-history":[{"count":0,"href":"https:\/\/www.idsein.fr\/en\/wp-json\/wp\/v2\/pages\/5543\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.idsein.fr\/en\/wp-json\/wp\/v2\/pages\/5494"}],"wp:attachment":[{"href":"https:\/\/www.idsein.fr\/en\/wp-json\/wp\/v2\/media?parent=5543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}